2217P Randomized phase II study of NaliCap compared to NAPOLI-1 in gemcitabine-pretreated advanced pancreatic cancer: PC-NaliCap study
Joo Hee Yoon, M.A. Lee, W.K. Bae, Chong Woo Yoo et autres
0 citationsAnnals of Oncology
M.A. Lee
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
24Publications signalées
340Citations signalées
3Affiliations récentes
Institutions déclarées
Domaines associés
Colorectal Cancer Treatments and StudiesGastric Cancer Management and OutcomesCancer Treatment and PharmacologyHepatocellular Carcinoma Treatment and PrognosisPancreatic and Hepatic Oncology Research
Publications récentes
LBA30 Zanzalintinib plus atezolizumab (zanza + atezo) vs regorafenib (rego) in patients (pts) with previously treated metastatic colorectal cancer (mCRC): Primary overall survival (OS) analysis from the randomized, open-label, phase III STELLAR-303 study
Anwaar Saeed, Y. S. Park, J. Tabernero, M.A. Lee et autres
0 citationsAnnals of Oncology
97P Asian subgroup analysis of the phase III LEAP-017 trial of lenvatinib plus pembrolizumab vs standard-of-care in previously treated metastatic colorectal cancer (mCRC)
R-H. Xu, Zhangxin Chen, H-W. Teng, Hongming Pan et autres
1 citationAnnals of Oncology
970P Real-world multi-center study of systemic treatment after first-line atezolizumab plus bevacizumab for advanced hepatocellular carcinoma in Asia-Pacific countries
CK Lee, C. Yoo, S.J. Park, Hyeyoung Kim et autres
2 citationsAnnals of Oncology
677P Preliminary findings from a phase I, open-label, dose-finding study of SNB-101 in patients with advanced solid tumors
Yun Beom Sang, Youdan Kim, M.A. Lee, Sun Young Rha et autres
4 citationsAnnals of Oncology
104P Final analysis of the prospective, randomized phase II STAMP trial: Adjuvant gemcitabine plus cisplatin (GemCis) versus capecitabine (CAP) in node-positive extrahepatic cholangiocarcinoma (CCA)
Hyehyun Jeong, Kwang Pyo Kim, Jae Ho Jeong, Dae Wook Hwang et autres
1 citationAnnals of Oncology
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with metastatic colorectal cancer
Takayuki Yoshino, Andrés Cervantes, Hideaki Bando, Erika Martinelli et autres
81 citationsESMO Open
116P Clinical significance of serum-derived exosomal PD-L1 expression in patients with advanced pancreatic cancer
S.J. Park, Il Hwan Kim, M.A. Lee, K. Shin et autres
0 citationsImmuno-Oncology Technology
OD2-2 Trastuzumab plus FOLFOX for gemcitabine/cisplatin refractory HER2-positive biliary tract cancer: A multi-institutional phase II trial of the Korean Cancer Study Group (KCSG-HB19-14)
CK Lee, H.J. Chon, J. Chon, M.A. Lee et autres
2 citationsESMO Open
955P Prognostic factor analysis of atezolizumab-bevacizumab in unresectable hepatocellular carcinoma: Korean cancer study group (KCSG) study
Jaekyung Cheon, Changhoon Yoo, Jung Yong Hong, Han Sang Kim et autres
2 citationsAnnals of Oncology
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis treatment and follow-up of patients with localised colon cancer
Takayuki Yoshino, Guillem Argilés, Eiji Oki, Erika Martinelli et autres
92 citationsAnnals of Oncology
101P HIF1-α depletion overcomes resistance to oxaliplatin in colorectal cancer via ERK signalling pathway
S.J. Park, Jang Yong Kim, Kabsoo Shin, Hyangkyoung Kim et autres
0 citationsAnnals of Oncology
BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.